💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ferumoxytol

CHEMBL1201867 Phase 4 已批准 Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
231.5 g/mol
LogP
—
Phase
4

This injectable iron oxide nanoparticle preparation is used to treat iron deficiency anemia in adults with chronic kidney disease or other conditions who cannot tolerate or absorb oral iron. It can also serve as an MRI contrast agent due to its magnetic properties.

分子量

231.5300 g/mol

TPSA

4.00 Ų

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Epilepsy Migraine Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

作用机制

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
[O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3]

                

                

                
                

                    
InChI

                    
InChI=1S/3Fe.4O/q+2;2*+3;4*-2

                

                

                

                    
                    

                        
Molecular Formula

                        
Fe3O4

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
可旋转键数

                        
0

                    

                    
                    
                    

                        
重原子数

                        
7

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
This injectable iron oxide nanoparticle preparation is used to treat iron deficiency anemia in adults with chronic kidney disease or other conditions who cannot tolerate or absorb oral iron. It can also serve as an MRI contrast agent due to its magnetic properties.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ferumoxytol is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201867.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6432052.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.